

! UNDER EMBARGO until APRIL 11, 2022 !

This news release is strictly confidential until the embargo is released.

DO NOT publish anything before this date.

HPV INFECTION TREATABLE WITH VAGINAL GEL AND FOAM

CLINICAL STUDY SHOWS EFFECTIVE HPV TREATMENT

RESOLVING HPV INFECTION BY COST EFFECTIVE AND SIMPLE ADMINISTERED VAGINAL GEL OR FOAM

PRODUCT UNDERGOING MEDICAL CLASS 2 CERTIFICATION PROCESS IN CHINA.

Rotterdam, The Netherlands; 11 April 2022; Parx Materials NV (Euronext: MLPRX) announces successful clinical trial using the company's technology in vaginal gel and foam for the treatment of vaginal human papillomavirus (HPV) infections.

Cervical cancer is the 4th most common cancer among women worldwide, with 604.000 of new cases and over 340.000 deaths in 2020, according to the World Health Organization (WHO). More than 95% of cervical cancer is due to the human papillomavirus (HPV), and HPV types 16 and 18 are known to cause at least 70% of cervical cancers.

A current strategy to prevent cervical cancer is by administering a vaccine that works best when administered prior to exposure to HPV, recommended for girls in the age of 9 to 14 years. But a treatment for patients infected with HPV is not available today.

Parx Materials, together with a number of partners in China, has developed a foam and a gel product to treat vaginal HPV-infections. These are easy to administer products that can treat HPV infections in a user friendly and cost-effective manner. The gel or the foam product is administered by the patient themselves and does not require a physician. The products are currently in the process for medical class 2 certification in China, which is expected to be completed in June 2022.

Clinical trial

Concluded clinical trials of efficacy and safety of Parx anti-HPV gel and foam (results obtained by two HPV detection methods) show anti-HPV virus foams and gels can

effectively clear cervical high-risk HPV infection, reduce HPV-DNA viral load, and have a therapeutic effect on low-grade cervical lesions caused by high-risk HPV infection. The products can effectively reduce vaginal pH, increase the number of vaginal lactobacilli, increase catalase, reduce leukocyte esterase, improve the diversity and density of flora, and significantly improve vaginal cleanliness as well as reduce vaginal inflammatory reaction. Significant improvement in gynecological symptoms such as reduction of odor, secretions and itch.

Safety assessment

The safety evaluation of blood and urine routine, liver and kidney function and electrocardiogram were carried out on the patients before and after treatment, and no abnormal changes were found, and the clinical application was safe.

With the introduction of the Parx anti-HPV gel and foam the first treatment comes available for women whom have attacked the HPV virus. An effective solution with a world-wide market and particularly interesting for African countries where cervical cancer is the number 2 most frequent cancer among women.

Parx Materials is currently assessing the strategy to take this product into the market and is inviting potential pharmaceutical partners to discuss partnerships for making these products available in Europe, Africa and USA.

The clinical tests were performed at the Hospital for Skin Disease/Institute for Dermatology/Chinese Academy of Medical Sciences/Peking Union Medical College (<http://www.pumcderm.net/>) in China under supervision of Prof. Shaoxi Wu. Professor Wu served as the deputy editor-in-chief and executive editor-in-chief of the Chinese Journal of Dermatology, the Journal of Clinical Dermatology, the Chinese Journal of Dermatology and Western Medicine, American and Chinese Journal of Dermatology and many others.

“Parx technology is a far more advanced technology in the field of antibacterial and antiviral technology. It has remarkable results in treating relevant skin diseases and protecting skin health.” according to Prof. Shaoxi Wu.

About Parx Materials

Parx Materials NV, founded in 2012 and a public company since 2018, listed on Euronext Access in Paris with symbol: MLPRX, has build-up an extensive knowledge on remedies against bacteria, viruses, biofilm, molds and fouling. The company is integrating solutions derived from biomimicry, using a body’s own trace element, to prevent bacteria and virus adhesion in roughly any polymer type. The technologies are proven to be suitable for food contact applications as well as medical applications such as permanent implants. The technology can prevent biofilm on implants, can help to solve skin conditions, can prevent bad smell, can improve wound healing and now prove to function as a solution against HPV infections.



Contacts

Investors:

Felix Guépin, CFO

+31 649389802

fg@parxmaterials.com

www.mlprx.com

Media:

Michaël van der Jagt, CEO

+31 654731725

mj@parxmaterials.com